A non-genetic engineering platform for rapidly generating and expanding cancer-specific armed T cells.

ABSTRACT:

Background

Cancer-specific adoptive T cell therapy has achieved successful milestones in multiple clinical treatments. However, the commercial production of cancer-specific T cells is often hampered by laborious cell culture procedures, the concern of retrovirus-based gene transfection, or insufficient T cell purity.

Methods

In this study, we developed a non-genetic engineering technology for rapidly manufacturing a large amount of cancer-specific T cells by utilizing a unique anti-cancer/anti-CD3 bispecific antibody (BsAb) to directly culture human peripheral blood mononuclear cells (PBMCs). The anti-CD3 moiety of the BsAb bound to the T cell surface and stimulated the differentiation and proliferation of T cells in PBMCs. The anti-cancer moiety of the BsAb provided these B

SUBMITTER: Chen YJ 

PROVIDER: S-EPMC10230823 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature